Solutions for
Individual Subjects
Axcelead offers the optimum solution in line with your research theme
Click here for details
Axcelead is the first integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having inherited the unique and comprehensive capabilities of drug discovery from Takeda Pharmaceutical Company Limited： “Experienced Scientists”, “Cutting-edge Technology Platform”, and “Huge Historical Drug Discovery Data”, and started its business in 2017.
Looking for a solution in terms of a specific research theme, stage or modality
Solutions for
Project Co-creation
Solution
We aim to achieve innovation through co-creation with our clients
Click Here for Details
New Modalities
The new modalities support epoch-making discovery research including breakthroughs in regenerative medicine, nucleic acids and peptide drug discovery
Click Here for Details
Consulting services
Our highly experienced and expert staff will take care of your non-clinical development strategy and work to solve any problems
Click Here for DetailsFor clients interested in out-licensing
Out-License Program
Aimed at bio-venture capitalists, academia, and companies planning to enter the pharmaceutical industry who wish to out-license
Click Here for DetailsNEWS
Orizuru Therapeutics and Axcelead DDP Collaborate on Drug Discovery Support Services Regarding iPS Cells
Teijin and Axcelead to Establish Drug Discovery Research JV
AXCELEAD DDP SELECTED AS PROJECT PARTNER FOR HARVARD BUSINESS SCHOOL IMMERSIVE FIELD COURSE
PICK UP
HTS is a service to identify hit compounds with high probability in a short period of time.
We enable improvement of drug development efficiency and seamless translational research!
We offer an optimal package service for you to achieve your goal, such as IND application and out-licensing
PEOPLE
Check out our latest scientific research, insights and passion for drug discovery.
2021.08.28
Omics analysis, creating the future of drug discovery research ～Mechanism exploration with multilayer-omics analysis～
Tomohiro Andou
2020.10.02
Ion channel drug discovery with leading-edge facilities and a strategic approach!～Drug discovery ability to overcome challenges～
Azusa Seki, Ryosuke Hibino, Mitsuru Hirano
2020.07.06
Ceaselessly advancing integrated safety assessment of the cardiovascular system
Hiroyasu Miyazaki
2020.04.04
Let’s explore the appeal of Axcelead Drug Discovery Partners’ hERG current assay! ～To be the best partner for cardiac toxicity assessment～
Kiyoshi Takasuna
CLIENTS
We enjoy the patronage of more than 100 facilities, including pharmaceutical companies, startups and academic institutions
